A real-world study found that 25% of patients on pemigatinib had extrahepatic cholangiocarcinoma, a subtype where the drug's FGFR2 fusion target is historically rare. This significant deviation from established biology suggests potential issues with physician-abstracted data, such as mislabeling or referral bias, highlighting the need for cautious interpretation of real-world patient cohorts.

The Destiny Breast 11 trial compared a new drug to a chemotherapy regimen (ACTHP) that many US oncologists no longer use. This choice of a less common control arm makes it difficult for them to directly compare the new treatment's efficacy against their own current standard (TCHP), complicating adoption.

The Sac o six nineteen trial showed compelling results adding BCG to a chemo-immunotherapy backbone. However, the standard of care has already shifted to a newer combination (enfortumab vedotin and pembrolizumab), making it difficult to translate the study's findings into current practice and complicating the design of future trials.

The current pace of innovation in CLL treatment means new options become available faster than long-term clinical trials can conclude. This creates a critical need for more efficient trial designs and validated intermediate endpoints that can provide reliable answers sooner.

The expected rapid approval of the highly effective RAS inhibitor daraxonrasib poses a dual crisis. It creates an urgent need for equitable patient access globally while simultaneously making future randomized trials against standard chemotherapy nearly impossible to recruit, as patients will be unwilling to join the control arm.

While other cancers had higher mutation prevalence, Iterion Therapeutics selected hepatocellular carcinoma (HCC) because of the dramatic drop-off in effective treatments after first-line therapy. This created a clear unmet need and a potential for a faster, smaller registration study, demonstrating a savvy commercial strategy.

Despite showing superior progression-free survival over chemotherapy, the FIGHT-302 trial doesn't establish pemigatinib as an automatic first choice or a "slam dunk." It solidifies its role as a strong option, with the final decision depending on patient preferences, tumor characteristics, and a detailed discussion of pros and cons versus chemo-immunotherapy.

For pancreatic cancer patients, the primary obstacle to receiving promising KRAS-targeted therapies is not drug efficacy but logistical access. There are far more eligible patients than available slots on clinical trials, creating a significant and "tragic" bottleneck in delivering cutting-edge care.

The necessary delays for screening, eligibility, and logistical setup for clinical trials and novel agents like tarlatamab can take weeks. This makes them unsuitable for patients with rapid, aggressive disease progression, forcing clinicians to rely on older, faster-acting cytotoxic therapies instead.